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 Elevated circulating levels of the gut microbiota-derived metabolite, trimethylamine N-
oxide (TMAO), are associated with adverse outcomes in heart failure (HF) (1-4). Geographical 
differences of TMAO levels or on their association with HF outcomes have not been reported. 
However, we have noticed differences in the reported relationship between TMAO levels and 
outcomes according to reported geographical region. Independent reports from a British acute 
HF cohort (1) and from a Norwegian chronic HF cohort (2) showed attenuation of association 
of TMAO levels with outcomes after adjustment for main confounders, namely renal function. 
In contrast, in a German chronic HF population, TMAO levels were reported to be associated 
with mortality and had a better predictive value than N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) even after adjustment for glomerular filtration rate (eGFR) (3). We therefore 
wondered whether geographical location might account for this apparent difference (5) and 
investigated this hypothesis using the BIOSTAT-CHF cohort (4, 6, 7), a multinational study 
done across 11 countries in Europe in which we recently reported the measurements of plasma 
TMAO levels and their association with outcomes (4). 
 A diet-based categorization by country of enrolment was performed using the European 
Nutrition and Health Report classification (8) into the Northern/Western group (NW: France, 
Netherlands, Norway, Sweden, and United Kingdom), Central/Eastern group (CE: Germany, 
Poland, Serbia, and Slovenia), and Southern group (S: Greece and Italy) (Figure 1). The 
primary study endpoint was 2-year all-cause mortality. The association between TMAO and 
mortality was assessed by Cox proportional hazards analysis within each geographical group, 
adjusted for the modified BIOSTAT full risk model (Figure 1) (6) and gender, and for further 
specific TMAO confounders: eGFR, and body mass index (BMI). The effects of geographical 
location on addition of TMAO or NT-proBNP to the BIOSTAT risk model for mortality and 
interaction with TMAO were investigated.  Further, genetic effects on TMAO by the enzyme 
critical for conversion of TMAO from its precursor TMA, the flavin-containing 
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monooxygenase isoform 3 (FMO3) gene (i.e. four common gene polymorphisms of the A allele 
of rs2266782 and rs1736557, G allele of rs2266780, and T allele of rs909530) (9), were 
investigated using linear regression under an additive mode of inheritance further adjusting for 
the first 10 genetic principle components. Genotyping was carried out on the Affymetrix 
Axiom UK Biobank array and called using Affymetrix Power Tools 1.16.1. A p-value of <0.05 
was considered statistically significant.  
 Of 2234 patients in BIOSTAT-CHF, 952 (43%) were classified as NW, 714 (32%) as 
CE, and 568 (25%) as S. Geographical differences in demographics, comorbidities, and 
mortality were in line with previous reports on geographical characteristics of patients with HF 
(i.e. CE patients showing a younger age, a higher percentage of ischemic disease, and different 
outcomes) (5). CE patients were younger, had higher eGFR, and higher percentage of ischemic 
aetiology compared to NW but were similar to S patients (Figure 1 and Table 1). When adjusted 
for age, eGFR, and BMI, TMAO levels in CE remained significantly lowest amongst regions 
(median [IQR]: 6.2 µM [4.8-7.8], 7.2 µM [5.5-8.8], and 6.5 µM [5.0-8.2] respectively for CE, 
NW and S, p for trend <0.001). Results were essentially similar when there was additional 
adjustment for protein intake (Maroni formula) (median [IQR]: 6.2 µM [4.8-6.8], 7.2 µM [5.4-
8.9], and 6.5 µM [5.0-8.5] respectively for CE, NW and S, p for trend <0.001). Approximately 
24% of patients (n=531) reached the primary endpoint during a median follow-up of 21.5 [15.7-
24.3] months. Mortality rate varied amongst regions [NW 26.7% (n=254), CE 22.0% (n=157), 
and S 21.1% (n=120), p for trend=0.019]. In a Cox model adjusted for confounders including 
BIOSTAT risk model factors, the CE group alone showed significant association of higher 
TMAO levels with mortality (HR: 2.56 (1.44-4.57); p=0.001) (Figure 1). When interaction 
between geographical differences with TMAO or NT-proBNP levels and outcome was 
investigated, a statistically significant interaction for TMAO alone was observed but not for 
NT-proBNP (p interaction= 0.033 and 0.586 respectively). Further, NT-proBNP levels were 
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significantly associated with mortality after adjustment for confounders in all groups. However,  
TMAO levels significantly improved risk prediction when added to the basic model (BIOSTAT 
risk model and eGFR, BMI and gender) in CE patients alone, as shown by changes in C-statistic 
(0.723 to 0.748, p=0.031), NRI (21.3 [0.1-42.6], p=0.049) and IDI (2.0 [0.7-3.4], p=0.003) 
(Supplementary table 1). In contrast, for NT-proBNP there was a statistically significant gain 
in C-statistic, NRI, and IDI in all groups (Supplementary table 1). Associations of four 
previously identified genetic variants in the FMO3 gene with TMAO levels were not observed 
(Supplementary table 2).  
 This is the first report on effects of regional differences on association between TMAO 
levels and mortality risk in HF.  There are two main findings of the present analysis. First, 
TMAO levels of HF patients differed by region, even after adjustment for confounders. Second, 
there was a different association with outcome by region (i.e. mortality risk of patients with 
elevated TMAO levels was higher in CE patients than in NW and S patients). In addition to 
these main findings, in CE patients, TMAO levels were predictive of mortality on C-statistic 
analysis as well as NT-proBNP levels. Finally, known FMO3 gene variants were not associated 
with TMAO levels.  Collectively, our findings demonstrate the different associations of TMAO 
with HF outcomes in a European population suggesting that geographical differences apart 
from measured demographic and associated comorbidities might represent at least one possible 
explanation for this (1-3). The BIOSTAT-CHF cohort has two features that made it an ideal 
cohort to investigate regional discrepancies. First, patients from different European regions 
(NW, CE and S) were well represented in our cohort. Second, with more than 99% of patients 
being Caucasian, the role of ethnicity and the genetic pool was mitigated as possible 
confounders of underlying geographical differences (5). However, there were several 
limitations in the present study. We did not have any information regarding the actual dietary 
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records, gut microbiota composition or intestinal permeability to confirm the impact of diet on 
TMAO levels.  
 In conclusion, geographical differences affect the levels and association of TMAO with 
heart failure mortality, regardless of main confounders. There may still be other under-
investigated factors that affect associations of TMAO and HF adverse outcomes (e.g. changes 
in gut flora with age, and association with dietary history and/or physical activity).  
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Table 1. Patient characteristics regarding geographical groups. 
 
  Northern/Western Central/Eastern Southern p for 
trend   (n=952) (n=714) (n=568) 
Demographics      
  Age 74 [64–80] † 67 [59–75] 68 [59–76] † <0.001 
  Male 627 (66%)* 548 (77%) 479 (84%) <0.001 
  Body mass index (kg/m2) 26.9 [23.7–30.9] * 27.5 [24.7–31.1] 27.5 [24.4–29.8] 0.005 
  Current smoker 122 (13%) 106 (15%) 84 (15%) 0.407 
  Ischemic aetiology 477 (51%)* 432 (62%) 305 (56%) <0.001 
  Hypertension 516 (54%)* 540 (76%) 345 (61%)* <0.001 
  Diabetes mellitus 273 (29%) 246 (35%) 211 (37%) 0.001 
  Atrial fibrillation 470 (49%) † 293 (41%) 243 (43%) 0.002 
  COPD 180 (19%) † 101 (14%) 106 (19%) 0.025 
  Previous HF hospitalisation 260 (27%)* 229 (32%) 214 (38%) <0.001 
  NYHA class (%) I/II/III/IV  2/34/51/12† 1/39/53/7 5/33/45/17† <0.001 
  LV ejection fraction (%) 30 [25–40] † 30 [25–36] 30 [25–35] <0.001 
Clinical signs      
  Pulmonary congestion 513 (57% )† 325 (46%) 311 (56%) † <0.001 
  Peripheral oedema 523 (69%) † 358 (55%) 222 (50%)* <0.001 
  Systolic blood pressure (mmHg) 120 [110–139] * 125 [110–140] 120 [110–130] * <0.001 
  Diastolic blood pressure (mmHg) 71 [63–83] * 78 [70–85] 70 [69–80] * <0.001 
  Heart rate (beat/min) 79 [68–95] † 75 [66–84] 75 [66–86] † <0.001 
Medication      
  Beta-blocker 755 (79%)* 629 (88%) 479 (84%) 0.017 
  ACE inhibitor or ARB 673 (71%)* 569 (80%) 396 (70%)* <0.001 
  MRA 379 (40%)* 475 (67%) 339 (60%) <0.001 
  Diuretics 950 (100%) 714 (100%) 568 (100%) 0.260 
Laboratory       
  Haemoglobin (g/dL) 13.0 [11.7-14.4] * 13.7 [12.3-14.7] 13.2 [11.8-14.4] * <0.001 
  Urea (mmol/L) 9.0 [6.7-13.1] 9.5 [6.9-15.0] 18.2 [12.5-26.1] <0.001 
  Sodium (mmol/L) 139 [137-141] * 140 [138-142] 139 [137-142] * <0.001 
Outcomes (2 years)      
  Mortality  254 (27%) † 157 (22%) 120 (21%) 0.019 
 
Data are expressed as median [interquartile range] for continuous variables or n (%) for categorical 
values. P values are quoted for Kruskal-Wallis tests for continuous variables and Chi-square tests for 
categorical variables. ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; 
COPD=chronic obstructive pulmonary disease; HF=heart failure; LV=left ventricular; 
MRA=mineralocorticoid receptor antagonist; NT-proBNP=N-terminal pro-B-type natriuretic peptide; 
NYHA=New York Heart Association;  
†Significantly higher compared to CE; *significantly lower compared to CE pairwise analyses.   
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Figure 1. Association between TMAO/NT-proBNP and all-cause mortality at 2 years according to geographical groups. 
Forest plot of the hazard ratio (HR) of 2-year mortality risk per log TMAO/NT-proBNP increase. Whiskers represent 95% confidence intervals (CI).HRs 
adjusted for modified BIOSTAT-CHF full risk model factors (age, log urea, haemoglobin, use of beta-blocker at baseline, log NT-proBNP/ log TMAO, 
ischemic aetiology, chronic obstructive pulmonary disease, diastolic blood pressure, and sodium), glomerular filtration rate, body mass index, and gender.  
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Supplementary table 1. Added value performance for TMAO or BNP over the BIOSTAT risk model according to geographical groups.  
  C-statistic 
p value NRI [% (95% CI)] p value IDI [% (95% CI)] p value 
  Basic model adding  
TMAO               
North and West 0.716 0.717 0.879 7.3 (-9.0 - 23.6) 0.381 0.1 (-0.1 - 0.2) 0.574 
Centre and East 0.723 0.748 0.031 21.3 (0.1 - 42.6) 0.049 2.0 (0.7 - 3.4) 0.003 
South 0.733 0.736 0.663 12.1 (-11.6 - 35.8) 0.316 0.4 (-0.4 - 1.3) 0.310 
NT-proBNP               
North and West 0.716 0.742 0.008 35.6 (19.5 - 51.7) <0.001 2.7 (1.4 - 4.0) <0.001 
Centre and East 0.723 0.754 0.026 50.9 (30.4 - 71.4) <0.001 4.2 (2.2 - 6.2) <0.001 
South 0.733 0.778 0.024  53.6 (30.9 - 76.3) <0.001 6.7 (3.9 - 9.6) <0.001 
IDI= integrated discrimination improvement; NRI= net reclassification improvement; NT-proBNP=N-terminal pro-B-type natriuretic peptide; 
TMAO=trimethylamine-N-oxide. Basic model: modified BIOSTAT risk model included age, log urea, haemoglobin, use of beta-blocker at baseline, ischemic 
aetiology, chronic obstructive pulmonary disease, diastolic blood pressure, and sodium, and eGFR, BMI, and gender. 
 
Supplementary table 2. Association between genetic variants of FMO3 and TMAO levels.  
 
SNP Position (b37) EA EAF Beta 95% CI P value 
rs2266782 171076966 A 0.399 -0.019 -0.091, 0.053 0.604 
rs1736557 171080080 A 0.072 -0.043 -0.105, 0.020 0.183 
rs909530 171083174 T 0.220 -0.008 -0.108, 0.092 0.878 
rs2266780 171083242 G 0.162 -0.009 -0.062, 0.045 0.756 
 
SNP= Single nucleotide polymorphism; EA= Effect allele; EAF= Effect allele frequency. Results are adjusted for gender, age, geographical location, BMI, 
eGFR, and the first 10 genetic principle components. 
 
